Payment overview · 2025
General Payments
$1,186.28
66 reported records · 16 companies
Healthcare provider profile · identity verified
Isabel Leticia Mora, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EAST ORANGE, NJ · NPI 1972167682
Verified facts
What the public records show
CMS Open Payments records show Isabel Leticia Mora, MD received $1,186.28 in general payments during 2025 across 66 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $169.01 | 14.2% | 9 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $155.37 | 13.1% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $145.83 | 12.3% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $104.10 | 8.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $100.47 | 8.5% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $96.04 | 8.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.44 | 7.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.66 | 6.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.28 | 5.8% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $51.83 | 4.4% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $39.43 | 3.3% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $29.19 | 2.5% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $21.86 | 1.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.28 | 1.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.19 | 1.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $14.30 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,186.28 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $155.37 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $112.03 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $104.44 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $104.10 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $98.25 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $96.04 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $94.21 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $70.76 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $70.66 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.24 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $66.24 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $51.83 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.59 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $39.43 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.40 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.42 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.26 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $29.19 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 86 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 176 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 218 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 84 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
73 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
176 | 51 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
218 | 49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 27 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 575 | 223 |
| Gabapentin | Gabapentin | 281 | 102 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 269 | 82 |
| Montelukast Sodium | Montelukast Sodium | 246 | 90 |
| Omeprazole | Omeprazole | 233 | 84 |
| Kerendia | Finerenone | 218 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 212 | 84 |
| Mirtazapine | Mirtazapine | 194 | 54 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 189 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 180 | 61 |
| Farxiga | Dapagliflozin Propanediol | 176 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 173 | 88 |
| Lisinopril | Lisinopril | 171 | 69 |
| Baclofen | Baclofen | 160 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 49 |
| Metformin Hcl | Metformin Hcl | 149 | 50 |
| Ezetimibe | Ezetimibe | 148 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 62 |
| Losartan Potassium | Losartan Potassium | 137 | 56 |
| Alendronate Sodium | Alendronate Sodium | 123 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 117 | 37 |
| Carvedilol | Carvedilol | 109 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 40 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 100 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 36 |
| Trazodone Hcl | Trazodone Hcl | 90 | 30 |
| Ozempic | Semaglutide | 89 | 30 |
| Eliquis | Apixaban | 86 | 27 |
| Famotidine | Famotidine | 86 | 40 |
| Mounjaro | Tirzepatide | 84 | 23 |
| Lidocaine | Lidocaine | 83 | 30 |
| Jardiance | Empagliflozin | 82 | 34 |
| Pregabalin | Pregabalin | 80 | 23 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 80 | 15 |
| Januvia | Sitagliptin Phosphate | 79 | 18 |
| Rybelsus | Semaglutide | 79 | 21 |
| Vascepa | Icosapent Ethyl | 78 | 30 |
| Linzess | Linaclotide | 73 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 73 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 28 |
| Meclizine Hcl | Meclizine Hcl | 71 | 29 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 68 | 18 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 65 | 20 |
| Prednisone | Prednisone | 64 | 52 |
| Naproxen | Naproxen | 63 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 21 |
| Methocarbamol | Methocarbamol | 59 | 31 |
| Meloxicam | Meloxicam | 56 | 29 |
| Buspirone Hcl | Buspirone Hcl | 55 | 12 |
| Metformin Hcl Er | Metformin Hcl | 55 | 24 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 53 | 12 |
| Trulicity | Dulaglutide | 50 | 17 |
| Nifedipine Er | Nifedipine | 49 | 19 |
| Repatha Sureclick | Evolocumab | 49 | 21 |
| Simvastatin | Simvastatin | 47 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | 17 |
| Donepezil Hcl | Donepezil Hcl | 44 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 44 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 22 |
| Tramadol Hcl | Tramadol Hcl | 41 | 29 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 11 |
| Betamethasone Valerate | Betamethasone Valerate | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Furosemide | Furosemide | 37 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 20 |
| Azithromycin | Azithromycin | 32 | 31 |
| Enalapril Maleate | Enalapril Maleate | 32 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 31 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 29 | 16 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 27 | 18 |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Levocarnitine | Levocarnitine | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Trulance | Plecanatide | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 12 |
| Finasteride | Finasteride | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,186.28 · 66 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, BREZTRI, CAPVAXIVE, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, FFRct, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REZDIFFRA, Rybelsus, UBRELVY, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error